On October 30, 2025, iBio, Inc. announced promising preclinical data for its IBIO-610 antibody, indicating an extended half-life of 33.2 days in non-human primates, potentially extending to 100 days in humans, which could reduce dosing frequency to once every six months. The results will be presented at ObesityWeek 2025 from November 4-7, 2025.